JYNNEOS vaccine effectiveness against mpox infection studied in New York City surveillanceDid the mpox vaccine work in New York City? A new report looks for answers

A surveillance report from New York City examined the effectiveness of the JYNNEOS vaccine in preventing diagnosed mpox infection. The observational study did not report sample size, follow-up duration, comparator group, or specific effectiveness results in the abstract. No effect size, absolute numbers, p-values, or confidence intervals were provided for the primary outcome of preventing diagnosed mpox infection.

Safety and tolerability data were not reported, including adverse events, serious adverse events, or discontinuations. The abstract did not mention study limitations, funding sources, or conflicts of interest.

As an observational surveillance report without reported results, this provides limited evidence for clinical decision-making. The absence of specific effectiveness data, comparator information, and safety outcomes prevents meaningful assessment of vaccine performance in this population. Clinicians should await peer-reviewed publication with complete methodology and results before drawing conclusions about JYNNEOS effectiveness in New York City.